{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:37Z","timestamp":1791347317606,"version":"4.3.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,31]]},"DOI":"10.1097\/qad.0b013e328360dbb4","type":"journal-article","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T12:43:11Z","timestamp":1363092191000},"page":"1933-1940","source":"Crossref","is-referenced-by-count":51,"title":["Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype"],"prefix":"10.1097","volume":"27","author":[{"given":"Helen M.","family":"McIlleron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schomaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phumla","family":"Sinxadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.C.","family":"Nuttall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermien","family":"Gous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Moultrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Eley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepta","family":"Merry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1011214","article-title":"Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.","volume":"365","author":"Madhi","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-10-20210130","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.5588\/ijtld.10.0538","article-title":"Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy.","volume":"15","author":"Bakeera-Kitaka","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"R4-10-20210130","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.109.027706","article-title":"Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.","volume":"37","author":"Belanger","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R5-10-20210130","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1124\/dmd.109.031393","article-title":"Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.","volume":"38","author":"Ogburn","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R6-10-20210130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","article-title":"Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.","volume":"57","author":"Wen","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-10-20210130","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"R8-10-20210130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R9-10-20210130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0b013e31819c33a3","article-title":"Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.","volume":"50","author":"Ren","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-10-20210130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13312-011-0153-3","article-title":"Serum nevirapine and efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.","volume":"48","author":"Shah","year":"2011","journal-title":"Indian Pediatr"},{"key":"R12-10-20210130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"R13-10-20210130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/01621459.1996.10476908","article-title":"Multiple imputation after 18 years.","volume":"91","author":"Rubin","year":"1996","journal-title":"J Am Stat Assoc"},{"key":"R14-10-20210130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516GT polymorphism on efavirenz concentrations in adults in South Africa.","volume":"14","author":"Cohen","year":"2009","journal-title":"Antivir Ther"},{"key":"R15-10-20210130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-7-8","article-title":"Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIVTB co-infected Thai adults.","volume":"7","author":"Uttayamakul","year":"2010","journal-title":"AIDS Res Ther"},{"key":"R16-10-20210130","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/clpt.2011.129","article-title":"Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.","volume":"90","author":"Ngaimisi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R18-10-20210130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/QAD.0b013e3283427e05","article-title":"Paradoxically elevated efavirenz concentrations in HIVtuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.","volume":"25","author":"Kwara","year":"2011","journal-title":"AIDS"},{"key":"R19-10-20210130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-011-1166-5","article-title":"The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.","volume":"68","author":"Gengiah","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R20-10-20210130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FPC.0b013e328328d577","article-title":"In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.","volume":"19","author":"Di Iulio","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R21-10-20210130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jac\/dkp033","article-title":"Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.","volume":"63","author":"Ramachandran","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R22-10-20210130","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/605126","article-title":"CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.","volume":"200","author":"Leger","year":"2009","journal-title":"J Infect Dis"},{"key":"R23-10-20210130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R24-10-20210130","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":"Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.","volume":"66","author":"Wyen","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R27-10-20210130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","article-title":"Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.","volume":"155","author":"Parkin","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"R28-10-20210130","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/AAC.01833-10","article-title":"The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.","volume":"55","author":"Chigutsa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-10-20210130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/QAI.0b013e31805c9d52","article-title":"High prevalence of subtherapeutic plasma concentrations of efavirenz in children.","volume":"45","author":"Ren","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R30-10-20210130","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.01594-08","article-title":"Is the recommended dose of efavirenz optimal in young west African human immunodeficiency virus-infected children.","volume":"53","author":"Hirt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-10-20210130","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/QAI.0b013e318235e560","article-title":"Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.","volume":"58","author":"Fillekes","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-10-20210130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0b013e318040b29e","article-title":"Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.","volume":"45","author":"Saitoh","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R33-10-20210130","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJM199912163412502","article-title":"Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.","volume":"341","author":"Starr","year":"1999","journal-title":"N Engl J Med"},{"key":"R34-10-20210130","first-page":"4","article-title":"Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.","volume":"3","author":"La Porte","year":"2006","journal-title":"Rev Antiviral Ther"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e328360dbb4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T05:12:38Z","timestamp":1688101958000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201307310-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,31]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328360dbb4","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,31]]}}}